http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NI-202100048-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-52
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-52
filingDate 2021-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f15a0a70757e9a6c3c5ca2f8aba81520
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_448d67af7e66c259b6e1c30fb3f89ce4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d22b1841dc46f03667a582d2ae923f0f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1feebfb376113c74e7d945c79b63a9c5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b50029a567f39eeb1731deabedc58863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_327b3bdd37d5854e475cd814e1cfef05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f9e3907611dd7a2db4cf377722b79b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcec799b81eefa258491c20805db75d6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e806cb7043ec80951531290dc9d636dd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ffb082e9965bb5948bd33cbe98b29e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0339af61832296b8d192c681baeaff3f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f569dfc1f10e60cc4f0308eef5d1bfa0
publicationDate 2021-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber NI-202100048-A
titleOfInvention PRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV-INFECTED CELLS
abstract The present disclosure relates to pyrimidone derivatives of Formula I and their use for selectively inactivating HIV-infected GAG-POL expressing cells without concomitant cytotoxicity relative to HIV-undifferentiated cells, and for the treatment or prophylaxis of HIV infection. , or for the treatment, prophylaxis, or delay in the onset or progression of AIDS or AIDS-related complex (ARC).
priorityDate 2018-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535553
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4909

Total number of triples: 31.